Wada Jun, Kawashima Kazumasa, Onizawa Michio, Gunji Naohiko, Watahiki Yu, Sakuma Chiharu, Murakami Mai, Mochimaru Tomoaki, Miura Shunsuke, Ohira Hiromasa
Department of Gastroenterology, Fukushima Medical University School of Medicine, Japan.
Department of Cardiovascular Medicine, Fukushima Medical University, Japan.
Intern Med. 2025 Jul 15;64(14):2165-2169. doi: 10.2169/internalmedicine.4655-24. Epub 2024 Dec 26.
Mesalazine-induced pericarditis is rare, and most cases occur at the time of treatment initiation. A 30-year-old man with ulcerative colitis who had experienced remission for 2 years with mesalazine 2,000 mg/day subsequently experienced relapse. Therefore, the mesalazine dose was increased to 4,000 mg. Thereafter, hematochezia improved, but anterior chest pain developed. Chest radiography revealed marked cardiac dilation (cardiothoracic ratio, 63%) and echocardiography revealed pericardial effusion. Adverse events associated with mesalazine should be carefully monitored, not only at the time of treatment initiation but also after dose escalation.
美沙拉嗪诱发的心包炎很罕见,且大多数病例发生在治疗开始时。一名30岁的溃疡性结肠炎男性患者,曾以每日2000毫克美沙拉嗪维持缓解状态达2年,随后病情复发。因此,美沙拉嗪剂量增至4000毫克。此后,便血症状改善,但患者出现了前胸疼痛。胸部X线检查显示心脏明显扩大(心胸比率为63%),超声心动图显示心包积液。不仅在治疗开始时,而且在剂量增加后,都应密切监测与美沙拉嗪相关的不良事件。